Exact Sciences enrolled its first patient in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study, the company announced today.

According to a release, the study will evaluate the clinical performance, patient and provider experience and psychological impact of MCED testing over a five-year period.

“Exact Sciences is dedicated to advancing an MCED test, as it offers a highly promising way to make an impact on the burden of cancer,” Exact Sciences Chief Medical Officer and Vice President of Multi-Cancer Early Detection Tom Beer, M.D., said in a statement. “Our collaboration with Baylor Scott & White and Endeavor Health is a crucial step forward and represents a tremendous opportunity to help transform cancer care.”

The study, which aims to enroll up to 25,000 patients from diverse backgrounds, will take place at Baylor Scott & White Health in Texas and Endeavor Health in Illinois. The patients, 50-80 years old with no history of cancer, will participate in annual MCED testing for three years and two additional years of follow-up data collection.

Endeavor Health will start enrolling patients this fall.